Europe

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company’s first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion’s College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion’s total workforce in Ireland to almost 500.

[Read More]

Study: Clinical trial transparency improving

Thursday, May 7, 2015

Transparency amongst industry-sponsored clinical trials continues to improve with results of 90% of trials on all new medicines approved by the EMA in 2012 disclosed within a 12-month timeframe, according to an Association of the British Pharmaceutical Industry (ABPI) study.

[Read More]

EMA tightens rules on ‘revolving door’ for committee members and experts

Thursday, May 7, 2015

The EMA has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the agency’s declaration of interest form.

[Read More]

Report: Transparency, cooperation help reduce high prices for new medicines

Friday, March 27, 2015

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe. The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost-effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

[Read More]